Similarly, the pharmacological inhibition of PTP1B in low-density lipoprotein receptor (LDLR)-deficient mouse model of atherosclerosis reduced plaque size and vascular expression of MCP-1 in addition to improving adiposity and insulin response [83]. This evidence concerns the gene PTPN1 and atherosclerosis.